Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial Filip Jansåker, Sara Thønnings, Frederik Boëtius Hertz, Thomas Kallemose, Jan Værnet, Lars Bjerrum, Thomas Benfield, Niels Frimodt- Møller, Jenny Dahl Knudsen EClinicalMedicine Volume 12, Pages 62-69 (July 2019) DOI: 10.1016/j.eclinm.2019.06.009 Copyright © 2019 Terms and Conditions
Fig. 1 Study flowchart * 125 With baseline bacteriuria (69.4%). † 122 With baseline bacteriuria (64.9%). ‡ No clinical nor bacteriological follow-up data received. § Follow-up questionnaire missing in 8 and 6 participants in 5-day and 3-day arm, respectively. Note: The number of cases assessed for eligibility at General Practitioner Clinics were not recorded because of financial and logistics imitations. EClinicalMedicine 2019 12, 62-69DOI: (10.1016/j.eclinm.2019.06.009) Copyright © 2019 Terms and Conditions
Fig. 2 Symptom resolution over time. The cumulative UTI symptom score (i.e. for the symptoms dysuria, frequency and urgency) was calculated daily. Each symptom was scored 0–3 points (i.e. none, mild, moderate or severe) daily in the participant reported diary. EClinicalMedicine 2019 12, 62-69DOI: (10.1016/j.eclinm.2019.06.009) Copyright © 2019 Terms and Conditions